The clinical significance of our work is that the application of CCK-BR antagonist therapy to human subjects with hepatic injury, chronic inflammation, or fibrosis with proglumide could potentially decrease the risk for the development of HCC. Here, CCKBR is linked to hepatocellular carcinoma.